Monday, March 19, 2018 12:11:55 PM
Keough was the CEO of OPD Holdings aka Thru Pharma and Dakota Life Sciences prior to the completion of their merger with Kasten.
Keough was a CEO when he hired ViaDerma's CEO, Christopher Ayo Otiko, to work on his proprietary projects. Then Otiko took what he learned through his work and started ViaDerma using Keough's trademarked technology. Otiko referred to Diabecline as ViaDerma's Lead Product on the VDRM website after executing a contract that states he would never compete. He went so far as to claim the 2012 Edison Award for Diabecline was an Award given to ViaDerma. Again, Keough owns the Trademark on Diabecline, and the underlying technology that he claims Otiko used in his 2017 Provisional Patent Applications.
Keough has no known alias.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM